NEW YORK, NY / ACCESSWIRE / February 10, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced its intent to offer, subject to market conditions and other factors, $150 million aggregate ...

Blessed with its first-ever FDA approval, little-known Kadmon is revving up the commercial engine to debut its new graft-versus-host disease drug by summer’s end. Kadmon plans to launch Rezurock, also ...

Looking to bolster Sanofi's portfolio of marketed drugs and pipeline prospects, CEO Paul Hudson went on a dealmaking spree last year. That included the drugmaker's $1.9 billion buyout of Kadmon, where ...

According to financial terms announced Wednesday, Sanofi will pay $9.50 for each share of Kadmon, a premium of 79% over the company’s $5.30 closing stock price on Tuesday, and about 113% more than the ...

New York biotech Kadmon is on course to file for FDA approval of belumosudil for chronic graft versus host disease (GVHD) after it hit the mark in a pivotal trial. GVHD is a common and often fatal ...

Kadmon has filed to go public in a $140 million IPO. But if it makes the leap, it will be without founder Sam Waksal anywhere near the premises. The biotech filed its S-1 today, spelling out Waksal’s ...

NEW YORK, NY--(Marketwired - Sep 24, 2014) - Kadmon Corporation, LLC announces today that Harlan W. Waksal, M.D., has joined the Company as its President and Chief Executive Officer after serving as a ...

Adds Rezurock™ (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD) after failure of at least two ...

NEW YORK, NY / ACCESSWIRE / February 11, 2021 / Kadmon Holdings, Inc. (Nasdaq:KDMN) today announced the pricing of $200 million aggregate principal amount of 3.625% convertible senior notes due 2027 ...